Bharat Biotech’s Vaccine Approved For Children Between 12-18 Years, DCGI Gives Approval

Share this News:

New Delhi, 25th December 2021: Amidst the new threat of corona rising in the country, approval has been given to vaccinating children between 12-18 years. 

The Drug Controller General of India (DCGI) has approved Bharat Biotech’s Covaxin for emergency use on children and adolescents aged 12 to 18 years, amid the threat of a new variant of the coronavirus Omicron.   

Bharat Biotech’s Covaxin is now the second vaccine approved for use on children in India. Prior to this, ZyCoV-D was the first vaccine approved by the DCGI for children above 12 years of age and older. However, for the time being, the central government had decided to give the dose of the vaccine only to adults.

At the same time, Covaxin will be given to children in two doses. There will be an interval of 28 days between the first and second dose. The vaccine spacing and dosage will be the same for adults and children, according to trial data submitted to the government.

Children getting the vaccine in America and Europe

According to reports, the Subject Expert Committee (SEC) in October recommended the DCGI for emergency use of Covaxin for children. If we talk about children’s vaccines in the world, then Pfizer Biotech is making a vaccine for children above 5 years. This vaccine has already started in America and Europe.